FDA clears IND application for novel anti-fibrotic drug AK3280 by ArkBio, leading to Phase 2 clinical trial for IPF.

Unusual Whales
2026.02.12 04:20
On February 11, 2026, Shanghai Ark Biopharmaceutical Co., Ltd. revealed that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AK3280. This drug is a new anti-fibrotic treatment aimed at treating idiopathic conditions. This development signifies a significant step forward in the company's efforts to introduce innovative therapies into the market.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer